Literature DB >> 27566129

A practical guide to assess the Nancy histological index for UC.

Aude Marchal-Bressenot1, Alexis Scherl2, Julia Salleron3, Laurent Peyrin-Biroulet4,5.   

Abstract

Entities:  

Keywords:  HISTOPATHOLOGY; IBD CLINICAL; ULCERATIVE COLITIS

Mesh:

Year:  2016        PMID: 27566129      PMCID: PMC5099187          DOI: 10.1136/gutjnl-2016-312722

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
Recently, we published the first validated index to assess histological disease activity in UC.1 We believe that some clarifications have to be made regarding the assessment of this index in both clinical practice and clinical trials. Three histological criteria have to be assessed. The first criterion is the presence of mucosal ulceration defined by the loss of colonic crypts replaced with ‘immature’ granulation tissue (defined as disorganised blood vessels with extravasated neutrophils) or the presence of fibrinopurulent exudate. The presence of only epithelial stripping should not be considered as ulceration. ‘Ulceration’ (grade 4 of the Nancy index corresponding to severely active disease) is simply defined by the presence or absence of this criterion on biopsy specimen (figure 1A, B).
Figure 1

(A) Ulceration of colonic mucosa with inflamed granulation tissue corresponding to grade 4 of the Nancy index (HES ×200). (B) Ulceration of colonic mucosa with neutrophils in fibrin corresponding to grade 4 of the Nancy index (HES ×200). (C) Presence of multiple clusters of neutrophils in lamina propria and/or in epithelium that are easily apparent. Acute inflammatory cells infiltrate is moderate to severe, corresponding to grade 3 of the Nancy index. (HES ×200). (D) Presence of few or rare neutrophils in lamina propria or in the epithelium that are difficult to see. Acute inflammatory cells infiltrate is mild, corresponding to grade 2 of the Nancy index (HES ×200). (E) Biopsy specimen showing no acute inflammatory cells infiltrate and presence of a moderate-to-severe increase in chronic inflammatory cells number corresponding to grade 1 of the Nancy index (HES ×200). (F) Biopsy specimen showing a mild increase in chronic inflammatory cell number. In this case, it defines a grade 0 of the Nancy index (HES ×200). HES, hematoxylin-eosin-saffron.

(A) Ulceration of colonic mucosa with inflamed granulation tissue corresponding to grade 4 of the Nancy index (HES ×200). (B) Ulceration of colonic mucosa with neutrophils in fibrin corresponding to grade 4 of the Nancy index (HES ×200). (C) Presence of multiple clusters of neutrophils in lamina propria and/or in epithelium that are easily apparent. Acute inflammatory cells infiltrate is moderate to severe, corresponding to grade 3 of the Nancy index. (HES ×200). (D) Presence of few or rare neutrophils in lamina propria or in the epithelium that are difficult to see. Acute inflammatory cells infiltrate is mild, corresponding to grade 2 of the Nancy index (HES ×200). (E) Biopsy specimen showing no acute inflammatory cells infiltrate and presence of a moderate-to-severe increase in chronic inflammatory cells number corresponding to grade 1 of the Nancy index (HES ×200). (F) Biopsy specimen showing a mild increase in chronic inflammatory cell number. In this case, it defines a grade 0 of the Nancy index (HES ×200). HES, hematoxylin-eosin-saffron. If ulceration is absent on biopsy specimen, the pathologist has to assess the second histological criteria, which is ‘acute inflammatory cells infiltrate’. Acute inflammatory cells infiltrate is defined by the presence of neutrophils in lamina propria and/or epithelial cells, with three grades: Moderate to severe: presence of multiple clusters of neutrophils in lamina propria and/or in epithelium that are easily apparent. In this case, it defines grade 3 of the Nancy index (figure 1C). Mild: few or rare neutrophils in lamina propria or in the epithelium that are difficult to see. In this case, it defines grade 2 of the Nancy index (figure 1D). Absence: no neutrophils on biopsy specimen. Then, in the absence of neutrophils on biopsy specimen, pathologist has to assess ‘chronic inflammatory infiltrate’. Chronic inflammatory infiltrate is defined by the presence of lymphocytes and/or plasmocytes and/or eosinophils in lamina propria. Chronic inflammatory infiltrate has to be assessed by two grades: Moderate to severe: presence of an increase in chronic inflammatory cells number that are easily apparent. In this case, it defines a grade 1 of the Nancy index (figure 1E). No or mild: no or mild increase in chronic inflammatory cells number. In this case, it defines a grade 0 of the Nancy index (figure 1F).
  1 in total

1.  Development and validation of the Nancy histological index for UC.

Authors:  Aude Marchal-Bressenot; Julia Salleron; Camille Boulagnon-Rombi; Claire Bastien; Virginie Cahn; Guillaume Cadiot; Marie-Danièle Diebold; Silvio Danese; Walter Reinisch; Stefan Schreiber; Simon Travis; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2015-10-13       Impact factor: 23.059

  1 in total
  8 in total

Review 1.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

2.  Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease.

Authors:  Vanessa Mitsialis; Sarah Wall; Peng Liu; Jose Ordovas-Montanes; Tamar Parmet; Marko Vukovic; Dennis Spencer; Michael Field; Collin McCourt; Jessica Toothaker; Athos Bousvaros; Alex K Shalek; Leslie Kean; Bruce Horwitz; Jeffrey Goldsmith; George Tseng; Scott B Snapper; Liza Konnikova
Journal:  Gastroenterology       Date:  2020-05-16       Impact factor: 22.682

3.  Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.

Authors:  Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2020-09-27       Impact factor: 8.171

4.  18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.

Authors:  Yan Li; Benedikt Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Anna Katharina Koch; Ole Martin; Ken Herrmann; Hendrik Juette; Andrea Tannapfel; Jost Langhorst
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-24       Impact factor: 9.236

5.  Ulcerative Colitis in Response to Fecal Microbiota Transplantation via Modulation of Gut Microbiota and Th17/Treg Cell Balance.

Authors:  Chunlan Huang; Qixiang Mei; Lihong Lou; Zehua Huang; Yang Fu; Junjie Fan; Jingjing Wang; Nuoming Yin; Yi Zheng; Yingying Lu; Yue Zeng
Journal:  Cells       Date:  2022-06-05       Impact factor: 7.666

6.  Ursolic Acid Regulates Intestinal Microbiota and Inflammatory Cell Infiltration to Prevent Ulcerative Colitis.

Authors:  Qinsong Sheng; Fei Li; Guanping Chen; Jiacheng Li; Jing Li; YiFan Wang; Yingyan Lu; Qun Li; Mingqian Li; Kequn Chai
Journal:  J Immunol Res       Date:  2021-04-30       Impact factor: 4.818

Review 7.  Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for?

Authors:  Ondrej Fabian; Lukas Bajer
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

8.  Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.

Authors:  Renske W M Pauwels; Elisa Proietti; Christien J van der Woude; Lindsey Oudijk; Marie-Rose B S Crombag; Maikel P Peppelenbosch; Ursula Grohmann; Gwenny M Fuhler; Annemarie C de Vries
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.